BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 30309668)

  • 1. Graft-versus-host disease.
    Moreno DF; Cid J
    Med Clin (Barc); 2019 Jan; 152(1):22-28. PubMed ID: 30309668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of Cutaneous Graft-vs-Host Disease.
    Ballester-Sánchez R; Navarro-Mira M; Sanz-Caballer J; Botella-Estrada R
    Actas Dermosifiliogr; 2016 Apr; 107(3):183-93. PubMed ID: 26626500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life-threatening graft-vs-host disease.
    Vargas-Díez E; García-Díez A; Marín A; Fernández-Herrera J
    Clin Dermatol; 2005; 23(3):285-300. PubMed ID: 15896544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal tract and liver graft-versus-host disease in pediatric patients with hematopoietic progenitor cell transplantation at a tertiary care center in Mexico.
    Jaramillo-Esparza CM; Consuelo-Sánchez A; Acosta-Rodríguez-Bueno CP; Ramón-García G; Sadowinski-Pine SW; Escobar-Sánchez MA; Castorena-Villa I; Gaytán-Morales F; Vázquez-Frias R
    Rev Gastroenterol Mex (Engl Ed); 2018; 83(4):385-392. PubMed ID: 29486973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
    Talmadge JE
    Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
    Aizawa K; Peltier D; Matsuki E; Toubai T
    Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical update on graft-versus-host disease in children.
    Goddard DS; Horn BN; McCalmont TH; Cordoro KM
    Semin Cutan Med Surg; 2010 Jun; 29(2):92-105. PubMed ID: 20579598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Graft-versus-host disease management.
    Mistrik M; Bojtarova E; Sopko L; Masakova L; Roziakova L; Martinka J; Batorova A
    Bratisl Lek Listy; 2016; 117(7):388-96. PubMed ID: 27546540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute graft-vs-host disease: pathobiology and management.
    Goker H; Haznedaroglu IC; Chao NJ
    Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Graft-versus-host disease: a complex long-term side effect of hematopoietic stem cell transplant.
    Barton-Burke M; Dwinell DM; Kafkas L; Lavalley C; Sands H; Proctor C; Johnson E
    Oncology (Williston Park); 2008 Oct; 22(11 Suppl Nurse Ed):31-45. PubMed ID: 19856578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease.
    Divito SJ; Aasebø AT; Matos TR; Hsieh PC; Collin M; Elco CP; O'Malley JT; Bækkevold ES; Reims H; Gedde-Dahl T; Hagerstrom M; Hilaire J; Lian JW; Milford EL; Pinkus GS; Ho VT; Soiffer RJ; Kim HT; Mihm MC; Ritz J; Guleria I; Cutler CS; Clark RA; Jahnsen FL; Kupper TS
    J Clin Invest; 2020 Sep; 130(9):4624-4636. PubMed ID: 32516138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal management of chronic graft-versus-host disease in children.
    Jacobsohn DA
    Br J Haematol; 2010 Aug; 150(3):278-92. PubMed ID: 20553274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Micronutrients in Graft-VS.-Host Disease: Immunomodulatory Effects of Vitamins A and D.
    Chen X; Mayne CG
    Front Immunol; 2018; 9():2853. PubMed ID: 30574143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-versus-host disease: review and nursing implications.
    Mattson MR
    Clin J Oncol Nurs; 2007 Jun; 11(3):325-8. PubMed ID: 17623617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute and chronic skin graft-versus-host disease--pathophysiological aspects.
    Socié G; Peffault de Latour R; Bouziz JD; Rybojad M
    Curr Probl Dermatol; 2012; 43():91-100. PubMed ID: 22377923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress and prospects: graft-versus-host disease.
    Mastaglio S; Stanghellini MT; Bordignon C; Bondanza A; Ciceri F; Bonini C
    Gene Ther; 2010 Nov; 17(11):1309-17. PubMed ID: 20508597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of mixed lymphocyte culture with chronic graft-versus-host disease following allogeneic stem cell transplantation.
    Visentainer JE; Lieber SR; Persoli LB; de Souza Lima SC; Vigorito AC; Aranha FJ; Eid KA; Oliveira GB; Miranda EC; de Souza CA
    Braz J Med Biol Res; 2002 May; 35(5):567-72. PubMed ID: 12011942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Graft-Versus-Host Disease.
    Ramachandran V; Kolli SS; Strowd LC
    Dermatol Clin; 2019 Oct; 37(4):569-582. PubMed ID: 31466596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation.
    Sahin U; Dalva K; Gungor F; Ustun C; Beksac M
    Ann Hematol; 2018 Jun; 97(6):1027-1039. PubMed ID: 29549412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.